CommercialCoverageLow impact
Temsirolimus (Torisel) (CPB 0873, reviewed 2026-10-08)
Aetna·Oncology, Hematology·Medical Policy
We identified it
Oct 13, 2026
Summary
This is a policy review (not a change) of Aetna's Clinical Policy Bulletin 0873 for temsirolimus (Torisel), last reviewed 2026-10-08. The policy defines approved indications (endometrial carcinoma, mantle cell lymphoma, renal cell carcinoma, soft tissue sarcoma, uterine sarcoma, and rhabdomyosarcoma), continuation criteria, dosing, and designates all other indications as experimental/investigational. No policy modifications or effective date changes are stated in the source document.
Action Required
No immediate action required. This document is a policy review dated 2026-10-08, not a policy change notice with a stated effective date. Billing and authorization teams should retain this bulletin for reference to confirm current Aetna coverage criteria for temsirolimus requests. Verify applicability by checking whether Aetna has issued a separate, dated change notice that supersedes or modifies this review. Use the approved indications and ICD-10 codes listed to determine prior authorization requirements for claims submitted to Aetna.